394 related articles for article (PubMed ID: 15807861)
1. Dichotomy of protective cellular immune responses to human visceral leishmaniasis.
Khalil EA; Ayed NB; Musa AM; Ibrahim ME; Mukhtar MM; Zijlstra EE; Elhassan IM; Smith PG; Kieny PM; Ghalib HW; Zicker F; Modabber F; Elhassan AM
Clin Exp Immunol; 2005 May; 140(2):349-53. PubMed ID: 15807861
[TBL] [Abstract][Full Text] [Related]
2. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers.
Kamil AA; Khalil EA; Musa AM; Modabber F; Mukhtar MM; Ibrahim ME; Zijlstra EE; Sacks D; Smith PG; Zicker F; El-Hassan AM
Trans R Soc Trop Med Hyg; 2003; 97(3):365-8. PubMed ID: 15228261
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study.
Khalil EA; Musa AM; Modabber F; El-Hassan AM
Ann Trop Paediatr; 2006 Dec; 26(4):357-61. PubMed ID: 17132302
[TBL] [Abstract][Full Text] [Related]
4. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.
Mahmoodi M; Khamesipour A; Dowlati Y; Rafati S; Momeni AZ; Emamjomeh M; Hejazi H; Modabber F
Clin Exp Immunol; 2003 Nov; 134(2):303-8. PubMed ID: 14616791
[TBL] [Abstract][Full Text] [Related]
5. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG.
Misra A; Dube A; Srivastava B; Sharma P; Srivastava JK; Katiyar JC; Naik S
Vaccine; 2001 May; 19(25-26):3485-92. PubMed ID: 11348715
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
Musa AM; Khalil EA; Mahgoub FA; Elgawi SH; Modabber F; Elkadaru AE; Aboud MH; Noazin S; Ghalib HW; El-Hassan AM;
Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
[TBL] [Abstract][Full Text] [Related]
7. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
8. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
Daifalla NS; Bayih AG; Gedamu L
Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
[TBL] [Abstract][Full Text] [Related]
9. Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis.
Garg R; Gupta SK; Tripathi P; Hajela K; Sundar S; Naik S; Dube A
Vaccine; 2006 Apr; 24(15):2900-9. PubMed ID: 16448729
[TBL] [Abstract][Full Text] [Related]
10. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis.
Kaye PM; Curry AJ; Blackwell JM
J Immunol; 1991 Apr; 146(8):2763-70. PubMed ID: 1901883
[TBL] [Abstract][Full Text] [Related]
11. Leishmanial antigens in liposomes promote protective immunity and provide immunotherapy against visceral leishmaniasis via polarized Th1 response.
Bhowmick S; Ravindran R; Ali N
Vaccine; 2007 Aug; 25(35):6544-56. PubMed ID: 17655984
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic efficacy of high-molecular-weight antigenic fractions of a recent clinical isolate of Leishmania donovani against visceral leishmaniasis.
Tripathi P; Gupta SK; Sinha S; Sundar S; Dube A; Naik S
Scand J Immunol; 2008 Nov; 68(5):492-501. PubMed ID: 18803606
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
14. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-γ and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge.
Kushawaha PK; Gupta R; Sundar S; Sahasrabuddhe AA; Dube A
J Immunol; 2011 Dec; 187(12):6417-27. PubMed ID: 22079980
[TBL] [Abstract][Full Text] [Related]
15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
16. IL-12 enhances Th1-type responses in human Leishmania donovani infections.
Ghalib HW; Whittle JA; Kubin M; Hashim FA; el-Hassan AM; Grabstein KH; Trinchieri G; Reed SG
J Immunol; 1995 May; 154(9):4623-9. PubMed ID: 7722314
[TBL] [Abstract][Full Text] [Related]
17. Surrogate markers of immunity to Leishmania major in leishmanin skin test negative individuals from an endemic area re-visited.
Nylén S; Khamesipour A; Mohammadi A; Jafari-Shakib R; Eidsmo L; Noazin S; Modabber F; Akuffo H
Vaccine; 2006 Nov; 24(47-48):6944-54. PubMed ID: 17049693
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory cellular responses of cured Leishmania-infected patients and hamsters against the integral membrane proteins and non-membranous soluble proteins of a recent clinical isolate of Leishmania donovani.
Garg R; Gupta SK; Tripathi P; Naik S; Sundar S; Dube A
Clin Exp Immunol; 2005 Apr; 140(1):149-56. PubMed ID: 15762886
[TBL] [Abstract][Full Text] [Related]
19. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
Choudhury R; Das P; De T; Chakraborti T
Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma levels of interferon (IFN)-gamma, IFN-gamma inducing cytokines, and IFN-gamma inducible CXC chemokines in visceral leishmaniasis.
Hailu A; van der Poll T; Berhe N; Kager PA
Am J Trop Med Hyg; 2004 Nov; 71(5):561-7. PubMed ID: 15569785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
